The OVAL Study: A Randomized Controlled Double-Arm Open-Label Multi-Center Study of VB-111 Combined with Paclitaxel vs. Paclitaxel Monotherapy for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer

Brief description of study

You are being asked to take part in this study because you have recurrent, platinum-resistant ovarian cancer. This means your ovarian cancer has grown or has recurred within 180 days of completing treatment with a platinum-containing chemotherapy. Patients who are not in a study are usually treated with standard chemotherapy with or without a biologic drug. The purpose of this study is to compare the efficacy and safety of the experimental drug VB-111 in combination with the standard chemotherapy drug paclitaxel compared to using paclitaxel combined with placebo.

Clinical Study Identifier: s17-00785 Identifier: NCT03398655

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.